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Abstract 
Ischemic mitral regurgitation (IMR) is a frequent and serious complication of coronary 
artery disease, associated with considerable increases in mortality and morbidity for the patient. 
While the benefits of simultaneous revascularization and mitral valve surgery are uncontested in 
moderate to severe cases, the ideal surgical approach to the valve is yet to be established.  
Mitral valve repair (MVr) has shown benefits over replacement (MVR) in nonischemic 
primary mitral regurgitation, but its superiority in the treatment of IMR has not been replicated. 
New randomized trials suggest it may be in fact non-superior, due to significantly greater 
reoperation rates amidst similar mortality in the long run. 
Such discrepant outcomes likely stem from the distinct pathophysiology of IMR. Unlike 
its etiologically degenerative counterparts, IMR does not derive from direct damage to the valve 
leaflets, but rather from dysfunction of its sub-valvular apparatus and the left ventricular wall, in 
the context of acute or chronic ischaemia. Echocardiographic data points to remodelling of the 
left ventricle, with subsequent papillary muscle displacement, increased leaflet tethering and 
inefficient coaptation, as the main responsible mechanism for ischemic mitral regurgitation. 
The purpose of this article is to review the currently available data, in an attempt to 
better understand IMR’s unique pathophysiology and compare the different outcomes for mitral 
valve repair and replacement. 
 
Resumo 
A Regurgitação Mitral Isquémica (RMI) é uma complicação frequente e importante de 
doença arterial coronária, estando associada a aumentos consideráveis da mortalidade e 
morbilidade dos doentes. Apesar dos incontestados benefícios da revascularização e cirurgia 
valvular em simultâneo, a abordagem ideal à válvula não é ainda, nestes casos, consensual.  
Apesar das demonstradas vantagens da valvuloplastia mitral face à substituição em 
doentes com insuficiência mitral não-isquémica, estas não se verificam em doentes com RMI. 
Estudos randomizados recentes sugerem a não-superioridade da plastia face à substituição, 
devido a maiores taxas de reoperação, apesar de taxas de mortalidade semelhantes a longo-
prazo. 
Esta discrepância poderá resultar da fisiopatologia distinta da RMI. Ao contrário dos 
seus congéneres de etiologia degenerativa, a RMI não deriva do dano directo aos folhetos 
mitrais, mas antes da disfunção do aparelho sub-valvular  e do ventrículo esquerdo, em contexto 
isquémico, seja este agudo ou crónico. Estudos ecográficos sugerem que a distorção do 
ventrículo esquerdo, com subsequente deslocação dos músculos papilares, aumento das forças 
de ancoragem dos folhetos e coaptação ineficiente dos mesmos, são os grandes responsáveis 
pela RMI. 
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Este artigo tem como propósito fazer uma revisão dos estudos presentemente 
disponíveis, de forma a sumarizar o entendimento corrente da fisiopatologia da RMI e a 
comparar os diferentes outcomes da valvuloplastia e substituição valvular.  
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Introduction 
Mitral regurgitation (MR) is a condition whereby the incorrect coaptation of the 
mitral leaflets results in the retrograde blood flow from the left ventricle (LV) to the left 
atrium (LA). The term encompasses a wide variety of diseases and dysfunctions of the 
mitral valve apparatus with varying responses to medical and surgical treatments. As 
such, it is important to distinguish between primary MR (regurgitation due to organic 
dysfunction of the mitral valve) and secondary MR (regurgitation as a consequence of 
left ventricle remodelling). The latter comprehends mitral regurgitation in the context of 
idiopathic cardiomyopathy or as a result of acute/chronic coronary artery disease 
(CAD). The second of the two is termed Ischemic Mitral Regurgitation (IMR).
1
 
IMR is a frequent and serious complication of coronary artery disease.
2–7
 It may 
present acutely, in the setting of myocardial infarction (MI), usually with cardiogenic 
shock and hemodynamic instability, or chronically with long-standing CAD, in the 
absence of active ischemia.
8
 It is independently associated with increased cardiac 
mortality rates, even in mild cases, with direct correlation between severity and reduced 
survival.
4
 Its importance for patient prognosis and its difficult clinical recognisability 
makes it an important factor to monitor in patients with acute or chronic coronary artery 
disease.
5,6
 
Current guidelines recommend valvular surgery for patients with moderate to 
severe MR undergoing coronary artery bypass graft surgery (CABG) but do not specify 
which procedure constitutes the ideal surgical approach or under which circumstances 
to prefer either. Although MVr has demonstrated benefits over replacement in primary 
MR, the surgical strategy for IMR patients remains controversial, mostly due to the high 
rates of  recurrence with MVr and higher operative mortality after MVR.
1,9
 Decisions 
have been made difficult by the lack of randomized trials and the selection bias in the 
majority of retrospective studies when assigning patients to different surgery modalities 
(with the sickest patients undergoing MVR). 
Recently, a number of new randomized trials studying IMR have been 
published, providing us with new information while also corroborating some ideas 
previously suggested by a few retrospective cohort studies. It is therefore pertinent (and 
is the aim of this paper) to analyse this new information, couple it with the 
understanding of the mitral valve apparatus and that of the pathophysiology of IMR, in 
the hopes tto summarize information that aids in decision-making. 
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The Mitral Valve Apparatus – Anatomy and Function 
In order to understand IMR it is paramount to recall that the function of the 
mitral valve depends not only on the function of its leaflets but on the integrity and fine 
coordination of all the structures that make up the Mitral Valve Apparatus: the left 
atrial wall, the two mitral leaflets, the mitral annulus, the chordae tendineae and 
papillary muscles (which, together, make up the Subvalvular Apparatus), as well as the 
left ventricular wall (Figure 1).
10
 Dysfunction of the arterial blood supply to these 
structures is at the genesis of IMR, reason as to why it is briefly reviewed. 
 
 
Figure 1 – The Mitral Valve Apparatus and its situation  in the heart. 
  
Left Atrial Wall 
The left atrial wall influences the closure of the mitral leaflets through 2 
mechanisms: (1) contraction and relaxation (2) and dilatation. The first process results 
in the generation of ventriculoatrial gradient pressures, important to the closure of the 
leaflets.
11
 Despite this, the absence of said mechanism (atrial fibrillation, complete heart 
block, others) does not necessarily result in mitral regurgitation.
12
 On the other hand left 
atrial dilatation can, by itself, result in mitral regurgitation. As the left atrium is 
enlarged, there is a posterior and downward displacement of the posterior wall, resulting 
in increased tension of the posterior mitral leaflet and preventing its correct coaptation.
13
 
The left atrium is supplied mainly by branches of the left circumflex coronary 
artery.
14
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Figure 2 – The Mitral Valve and its relations 
Annulus 
The mitral valve orifice is oval shaped, like a D, with its anteromedial flat portion 
comprising the attachment of the anterior mitral leaflet in the subaortic region (Figure 
2). While this part of the annulus is fibrous and noncontractile, the posterolateral portion 
is muscular (with direct connections to the LV wall) and contracts during systole, 
asymmetrically closing the area of the orifice. It relates closely with the coronary sinus, 
posteriorly, which has implications for treatment.
15
 The annulus’ transverse diameter is 
greater than its anteroposterior counterpart, in a ratio of 4:3 with changes in this ratio 
(e.g atrial or ventricular dilatation) leading to dyfunction.
13
 
Leaflets 
The mitral valve is bicuspid, with an anterior (aortic or septal) leaflet and a 
posterior (mural, or ventricular) leaflet. The anterior leaflet is larger, inserting in about 
one third of the annulus and is in fibrous continuity with the aortic valve through the 
aortic–mitral anulus.16,17 The smaller posterior leaflet inserts in the remaining two thirds 
of the annulus.  
The leaflets occupy a combined area of approximately double and a half the size 
of the annulus, resulting in a large area of coaptation.
10,18
 In situations where there is 
misalignment or displacement of the leaflets, part of this area is lost and excessive stress 
is placed upon the chordae, which may result in their rupture. Loss of pliability due to 
direct damage (e.g  fibrosis) to the leaflets also leads to dysfunction. However, 
particularly in IMR, mitral regurgitation also occurs in the presence of undamaged 
leaflets.  
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Chordae Tendinae and Papillary Muscles – The Subvalvular 
Apparatus 
The edges of the mitral valve are held below the level of the mitral orifice by the 
chordae tendinae, drawing the leaflets to closure and helping in the maintenance of 
competence. The majority of chordae tendineae originate from the anterolateral and 
the posteromedial papillary muscles of the left ventricle and attach mostly to the free 
edges of both the leaflets.
19
 The anterolateral papillary muscle emits chordae tendinae to 
the left half of the anterior and posterior leaflets, while the posteromedial papillary 
muscle tethers the right half side of both leaflets. There are usually 4 to 12 chordae 
originating from each papillary muscle group (with a possible range of 2 to 22). 
However, further chordal branching results in a number of chordae ranging from 12 to 
80 inserting to the mitral valve leaflet (Figure 3).
20
  
The anterolateral papillary muscle of the left ventricle possesses a double blood 
supply through one or more branches from the left anterior descending coronary artery 
and marginal branches of the circumflex coronary artery. The arterial supply of the 
posteromedial papillary muscle, on the other hand, is mediated solely by branches of 
the posterior descending coronary artery (which arises from either the right main 
coronary or left circumflex coronary arteries, according to the dominance of the heart).
14
 
This results in a greater likelihood of rupture for the posteromedial papillary muscle, as 
compared to its anteromedial counterpart.
21–23
  
 
     
Figure 3 – The Subvalvular Apparatus: chordae, papillary muscles and normal leaflet coaptation. 
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Left Ventricular Wall 
The left ventricle myocardium comprises of three differently oriented layers of 
muscle fibres (subepicardial, middle and subendocardial). The superficial and deep 
layers are anchored at the ventricular orifices to fibrous structures of the central fibrous 
skeleton of the heart, suggesting that myocardial contraction plays an active role in 
valvular function. Changes in the left ventricular wall (such as dilatation or akinesia) 
can negatively impact the function of the mitral valve, both through its connection to the 
fibrous structures of the heart and through the displacement of the region of 
myocardium immediately underlying the papillary muscles.
14
 
The left descending coronary artery supplies the majority of the blood to the 
interventricular septum through its septal branches and to the anterior wall of the left 
ventricle through its diagonal branches. The left circumflex coronary artery gives rise to 
the obtuse marginal arteries that supply the homonym margin of the heart and some of 
the inferior surface of the ventricle. The posterior descending coronary artery, which 
arises from the right main coronary artery in 85-90% of people, supplies blood to the 
posterior portion of the interventricular septum and inferior wall of the ventricle (right 
dominance). In these cases, it form a loop of collateral circulation with the LDA.  In the 
remaining 10-15% (those with left dominance) the posterior descending coronary artery 
originates from the circumflex artery, making the left ventricle more so dependent on 
the left coronary artery. 
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Ischemic Mitral Regurgitation 
Definition 
Ischemic Mitral Regurgitation is defined as Mitral Regurgitation due to ischemic 
heart disease and, as such, it must not be confused with mitral regurgitation from other 
causes that coexists with ischemic heart disease.  
The thresholds for severity classification of IMR are lower than those for 
primary MR, reflecting the graver nature of the disease and its prognostic implications. 
These and other criteria are described in Table 1. 
Table 1 - Echocardiographic criteria for the definition of severe valve regurgitation 
 Mitral Regurgitation 
Qualitative  
Valve morphology Flail leaflet/ruptured papillary muscle/ large coaptation defect 
Colour flow regurgitant jet  
 
Very large central jet or eccentric jet adhering, swirling, and 
reaching the posterior wall of the left atrium 
CW signal of regurgitant jet Dense/triangular 
Other Large flow convergence zone
a
 
Semiquantitative  
Vena contracta width (mm) ≥7 (>8 for biplane)b 
Upstream vein flow Systolic pulmonary vein flow reversal 
Inflow E-wave dominant ≥1.5 m/sd 
Other TVI mitral/TVI aortic >1.4 
Quantitative  Primary Secondary 
EROA (mm²) ≥40 ≥20 
RVol (ml/beat)  ≥60 ≥30 
+ enlargement of cardiac 
chambers/vessels  
LV, LA  
Adapted from Vahanian et al. – “ESC Guidelines on the management of valvular heart disease”, 2012. 
Ischemic Mitral Regurgitation occurs in two different settings: as a complication 
of Acute Myocardial Infarction (AMI), with a small subset of cases resulting from 
papillary muscle rupture (PMR), or as Chronic Mitral Regurgitation in patients with 
long standing ischemic heart disease. 
12 
 
Acute Mitral Regurgitation complicating Acute Myocardial 
Infarction – Acute IMR 
Presentation and Significance 
Significant (moderate to severe) mitral regurgitation is a common complication 
of AMI, presenting in 3 to 19% of patients.
2–7
 It usually presents itself as a flash 
pulmonary oedema or sudden angina with a de novo murmur.
24
 It is a known predictor 
of poor prognosis, with a graded relationship between severity and higher rates of 
severe heart failure, recurrent myocardial infarction and cardiovascular mortality.
2–7
 In a 
study by Lamas et al.(
4
), the cardiovascular mortality, in the 3 and a half years of 
follow-up, for myocardial infarction patients with acute IMR and without, were 29% 
and 12%, respectively.  
Pathophysiology 
IMR results from an unbalance between reduced closing forces and increased 
tethering forces acting on the mitral valve, as a result of myocardial injury.
25
 
Mechanisms that generate reduced closing forces include: reduction in LV contractility, 
altered systolic annular contraction, reduced synchronicity between the two papillary 
muscles and global LV dyssynchrony (especially in basal segments).
26,27
 The main 
mechanism responsible for increased tethering forces are changes in LV configuration 
(remodelling)
28–33
. The most common pattern observed involves a posterior infarction, 
usually transmural, leading to local LV remodelling and distortion, contributing to 
apical, posterior, and lateral displacement of the posterior papillary muscle. Through its 
chordal attachments, this displacement results in a more apical position of the leaflets 
and preventing correct coaptation (type IIIb dysfunction in the Carpentier's Surgical 
Classification of Mitral Valve Pathology – Figure 5).34,35 In other patients, LV 
remodelling occurs globally, with a more spherical LV where both papillary muscles are 
displaced, and in which annular dilatation plays a more important role (Figure 4).
36
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Figure 4 – Papillary Muscle displacement and leaflet tethering in ischemic heart disease. The displacement 
can be posterior (a) or global/both papillary muscles (b). 
Although previously regarded as a significant cause of IMR, papillary muscle 
necrosis does not necessarily result in mitral regurgitation, with the previously stated 
mechanisms playing a more important role in its pathogenesis.
26,29,37,38
 Kaul et al.(
26
) 
confirmed that reducing PM perfusion produced neither prolapse nor MR. In contrast, 
global hypoperfusion with LV dilatation, despite continued PM perfusion and 
thickening, caused MR with incomplete mitral leaflet closure in direct correlation with 
LV dysfunction.  
 
     
     Figure 5 – Carpentier’s Functional Classification.           Figure 6 – Papillary Muscle Rupture 
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Papillary Muscle Rupture 
Papillary muscle rupture is a serious and rare complication of acute myocardial 
infarction, with 24h-survival rates for nonsurgically treated patients ranging from 70% 
for partial ruptures to 25% for total ruptures.
39,40
 The loss of the tethering mechanism by 
a papillary muscle can result in flailing of the anterior and posterior leaflet, as they both 
receive chordae from the two papillary muscles (a type II dysfunction) (Figure 6). Of 
22 patients with acute myocardial infarction complicated by PMR studied by Barbour et 
al., 22% developed severe mitral regurgitation. The posteromedial papillary muscle has 
a threefold risk of rupture when compared to its anterolateral counterpart, which might 
result from the previously mentioned tenuous blood supply of the posteromedial 
papillary muscle.
21–23
 
Chronic Mitral Regurgitation complicating Ischemic Heart 
Disease – Chronic IMR 
Presentation and Significance 
The frequent coexistence of ischemic heart disease and MR due to nonischemic 
causes, makes the distinction between primary MR and IMR difficult. Patients with 
established chronic coronary artery disease present with a gradually increasing mitral 
regurgitation or a murmur that dates from the date of a previous MI is detected. In these 
settings and in the absence of a more likely etiology, ischemic mitral regurgitation is 
assumed. During the performance of surgery, the leaflets, papillary muscles and left 
ventricle can be inspected to confirm the diagnosis. However, fibrosis and dysfunction 
of these structures is sometimes indistinguishable from those caused by other etiologies. 
As with its acute counterpart, increasing severity of mitral regurgitation has an 
increasingly adverse effect on survival, regardless of type of treatment.
2,24,41,42
 
 
15 
 
              
Figure 7 – Annular dilatation (left) and papillary muscle elongation (right) as causes of mitral 
regurgitation. 
Pathophysiology 
The previously mentioned interaction between increased tethering forces and 
reduced closing forces, as well as the annular dilatation secondary to LV dysfunction 
(type I), are at the basis of mitral regurgitation in the chronic setting.
24,29
 In rare cases, 
the paradoxical elongation of a papillary muscle can also result in regurgitation through 
a type II dysfunction of the mitral valve apparatus (Figure 7).
43
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Ischemic Mitral Regurgitation – Treatment 
The particulars for non-surgical treatment are outside the scope of this paper and 
the reader is referred to the respective guidelines for detailed recommendations.  
Medical Therapy and Cardiac Resynchronization Therapy (CRT) 
Optimal medical therapy is the first-line therapy in the management of all 
patients with secondary MR and should be administered in accordance with the 
available guidelines for the management of HF.
44
 This includes ACE inhibitors, beta-
blockers and, in the event of HF, aldosterone antagonists. In the event of fluid overload 
the use of diuretics is indicated. The objective of medical treatment is to prevent 
myocardial ischemia, reduce and revert LV pathological remodelling and, thereby, 
decreasing the degree of ischemic mitral regurgitation. 
The use of CRT should also be in line with the related guidelines and may result 
in immediate reduction of MR severity through increased closed forces and 
resynchronization of papillary muscles. It is also possible that some of the reduction in 
tethering forces may result from LV reverse remodelling. The decrease in severity of 
regurgitation in responders correlates significantly with increased survival.
45
 
Surgical Treatment Options 
The surgical treatment of IMR comprises three different possible strategies: the 
performance of revascularization alone with Coronary Artery Bypass Grafting (CABG), 
CABG coupled with a mitral valve repair technique (Figure 9) or CABG simultaneous 
with mitral valve replacement (Figure 10).  
While most studies support the performance of surgery in severe cases of IMR, 
the lack of evidence that mitral valve surgery prolongs life in patients with moderate 
cases, has led to surgical revascularization alone being performed in some such cases. 
Notwithstanding, although isolated CABG may be beneficial for a number of patients 
with moderate IMR, the majority of papers support the use of combined surgery. 
CABG without valve procedure 
Akog et al.
46
 demonstrated, in a study of 136 patients, that CABG alone resulted 
in the improvement of moderate MR in 51% of the patients, with complete resolution in 
9% of those. All the same, 40% of patients remained with 3+ to 4+ MR, which led the 
18 
 
authors to conclude that CABG alone might not be the optimal therapy for most of these 
patients. Indeed, the majority of studies support the performance of combined surgery 
for the treatment of moderate IMR. Bonacchi et al.(
47
) compared the outcomes of 3 
groups of patients: Group I was composed of grade III-IV mitral regurgitation patients 
undergoing simultaneous CABG and mitral valve surgery, while the remaining two 
were composed of patients with low and moderate regurgitation, respectively, 
undergoing only CABG. They found that overall survival was similar between patients 
undergoing combined surgery and those with mild regurgitation undergoing CABG 
alone, whereas a significantly higher mortality rate was recorded in patients with 
moderate mitral regurgitation undergoing CABG alone. They also found that 
improvement of left ventricle ejection fraction (LVEF), as well as LV end-systolic and 
end-diastolic diameter (LVESD and LVEDD, respectively) occurred only in patients 
undergoing mitral valve surgery. The work done by Fattouch et al.(
48
) supports these 
findings of improvement in LV geometry, having also recorded greater improvements 
in the group undergoing mitral valve surgery of the New York Heart Association 
(NYHA) functional class, left atrium size, pulmonary artery pressure and heart failure 
symptoms at rest. However, like studies by Kim et al.(
49
) and Goland et al.(
50
) it did not 
record significant differences in overall mortality. A recent randomized trial by Michler 
et al.(
51
) found a lower rate of regurgitation recurrence among patients undergoing 
combined surgery, but no differences in mortality, LV geometry or survival. Combined 
surgery was also associated with an early hazard of increased neurologic and 
supraventricular arrhythmias. Because the additional risk of mitral valve surgery is not 
negligible and there is not enough conclusive evidence that mitral valve surgery actually 
improves survival, other factors such as comorbidities and poor LV function may 
dictate the treatment strategy for patients with moderate regurgitation. Sicker patients 
may benefit from the improved outcomes of CABG alone, without being subjected to 
the increased mortality of the combined approach.
43,52
 
CABG with a mitral valve procedure 
It has been established that the majority of patients with moderate-to-severe IMR 
require surgical revascularization with a concomitant mitral valve procedure (mitral 
valve replacement or repair) in order to experience improvement in mitral regurgitation. 
However operative mortality for these procedures is higher than in primary MR and  
19 
 
 
Figure 8 – Undersized ring annuloplasty. 
 
Figure 9 – Mitral valve replacement and types of valves. 
 
Figure 10 – Preservation of the subvalvular apparatus during replacement. 
20 
 
long-term outcomes are also inferior (although this correlates in part with the greater 
severity of the comorbidities among IMR patients). Lately, improved surgical 
techniques, such as an increase in the preservation of the subvalvular apparatus during 
MVR (Figure 10) and the use of the more effective downsized ring annuloplasty 
(Figure 8) during repair, have together with improved postoperative management 
resulted in superior outcomes (Table 3).
53,54
 
The latest European Society of Cardiology (ESC) guidelines from 2012 on the 
management of valvular heart disease recommend that severe mitral regurgitation 
should be corrected at the time of bypass surgery. Combined surgery should also be 
considered for patients with moderate MR, who are undergoing CABG. In symptomatic 
patients with severe IMR and severely depressed systolic function, isolated mitral valve 
surgery might be considered if comorbidities are low and revascularization is viable. 
For the remaining patients, including patients with mild IMR and those with severe 
IMR and depressed ventricular function but no viability for revascularization, optimal 
medical therapy is recommended. In the event of failure, by extended HF treatment, is 
currently the recommended option.
1
 These indications are summarized with their 
respective level of evidence in Table 2. 
The decision regarding which surgical technique to use remains controversial to 
this day and these latest guidelines do not make any particular recommendations.  
Table 2 - Indications for mitral valve surgery in chronic secondary mitral regurgitation 
 Class Level 
Surgery is indicated in patients with severe MRc undergoing 
CABG, and LVEF >30%. 
I C 
Surgery should be considered in patients with moderate MR 
undergoing CABG 
IIa C 
Surgery should be considered in symptomatic patients with severe 
MR, LVEF <30%, option for revascularization, and evidence of 
viability. 
IIa C 
Surgery may be considered in patients with severe MR, LVEF 
>30%,who remain symptomatic despite optimal medical 
management (including CRT if indicated) and have low 
comorbidity, when revascularization is not indicated. 
IIb C 
Adapted from Vahanian et al. – “ESC Guidelines on the management of valvular heart disease”, 2012. 
21 
 
Mitral Valve Surgery: Repair vs Replacement 
There have been several retrospective cohort studies published over the last 20 years, which 
have acted as the first evidence-based support for the decision making process in patients with 
moderate-to-severe IMR. However, due to their retrospective nature, they are inevitably flawed by 
the use of different surgical techniques in patients of the same study and selection bias in the use of 
a particular technique. Propensity scoring has been used in an attempt to resolve these 
shortcomings, but it is does not replace randomization (Table 3).  
Since 2012, only one randomized clinical trial comparing the two techniques, by The 
Cardiothoracic Surgical Trials Network (CTSN), has had published results, providing us with new 
insight with greater exemption from bias that have characterized previous papers, albeit limited by 
its currently short follow-up period. 
The techniques have registered different advantages and disadvantages in regards to 
different outcomes, reason as to why they are separately approached. 
Peri-operative mortality 
One of the flagships in favouring mitral valve repair over replacement has been its influence 
on operative mortality.  
The majority of retrospective cohort studies point towards inferior 30-day mortality rates in 
patients undergoing MVr as compared to MVR.
55–61
 However, the single randomized clinical trial 
by Acker et al.(
62
) comparing these techniques did not find a significant difference in 30-day 
mortality. These latest results suggest that operative mortality discrepancies in previous studies may 
result from selection bias in patients undergoing different surgical approaches, with the sickest 
patients usually undergoing mitral valve replacement. 
Late mortality 
In regards to late mortality, the conclusions vary with follow-up time. 
In studies with median follow-up ranging between 12 and 36 months, the differences in late 
mortality between MVr and MVR were found to not be statistically significant.
57,58,63,64
 However, 
when studies prolonged their follow-up length beyond 36 months, the differences in mortality 
increased, with patients treated with MVr presenting significantly reduced mortality rates.
47,56,59,60,65
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This suggests that studies without follow-up beyond 36 months might be unable to 
detect potential long-term mortality differences. 
A lot of the authors recognize, however, that on par with operative mortality, the 
difference in long-term survival might correlate with the baseline differences in 
comorbidities.
56,64
 Moreover, when propensity scoring is used to account for different 
baseline comorbidities, the difference is then deemed not statistically significant.
61,66,67
 
The 2-year results on the randomized clinical trial by Goldstein et al. (
68
) concluded that 
there was no significant cumulative mortality difference between treatment groups, with 
a rate of 19.0% in the repair group and 23.2% in the replacement group (hazard ratio 
with mitral-valve repair of 0.79; 95% confidence interval [CI], 0.46 to 1.35; P = 0.39 by 
the log-rank test). This supports the previous findings by the retrospective cohorts for 
follow-up up to 3 years but leaves the question of whether results beyond 36 months 
will differ. 
Regurgitation recurrence 
One of the major downfalls of mitral valve repair has been the significantly 
higher rates of at least moderate mitral regurgitation recurrence at mid-term follow-up, 
which has been shown to affect survival.
69,70
 A study by Gelsomino et al.(
71
) of 220 
patients undergoing CABG + undersized annuloplasty, reviewed patients’ MR status for 
up to 5 years. At 5-year echocardiography, 72% of the patients presented at least 
moderate recurrence.  
In virtually every retrospective cohort study comparing the two techniques, 
replacement has been superior to repair in this aspect, offering a more durable solution, 
with meta-analysis by Dayan et al.(
72
) and Virk et al.(
73
) concluding a risk of recurrence 
following MVr of 7 times that of replacement. The latest results from randomized 
patients corroborate these findings, with 58.8% of MVr patients recurring with 
moderate-to-severe regurgitation vs. 3.8% of MVR patients (P<0.001) at the two-year 
follow-up mark.
68
 The proposed explanation behind such results has been that, while the 
annular downsizing procedure reduces the effective regurgitation area, it does not 
correct the underlying pathophysiology of LV wall remodelling (localized or 
generalized) and subsequent leaflet tethering, resulting, in time, in recurrent 
regurgitation.
74
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The justification for why some patients recur and others don’t may lie in 
differing weights that the already described pathophysiological mechanisms play in 
different patients. There have been some studies that attempted to pinpoint predictors of 
regurgitation recurrence. Ciarka et al(
75
) studied LV and left atrial volumes and 
dimensions, LV sphericity index, mitral annular area, as well as mitral valve geometry 
parameters in patients undergoing CABG + MVr. They concluded that, of the studied 
parameters, the distal mitral anterior leaflet angle (hazard ratio 1.48, 95% confidence 
interval 1.32 to 1.66, p <0.001) and posterior leaflet angle (hazard ratio 1.13, 95% 
confidence interval 1.07 to 1.19, p <0.001) were independent determinants of MR 
recurrence at mid-term follow-up. However, it is of note that the study included both 
idiopathic dilated cardiomyopathy and IMR patients. Kron et al.(
76
) recently studied the 
116 IMR patients that underwent CABG + repair in the randomized trial for the 
CTSN(
62
), using logistic regression in an attempt to determine probability of recurrence 
based on echocardiographic measurements or clinical characteristics. They concluded 
that the presence of basal aneurysms and dyskinesis were the only characteristics 
strongly associated with recurrent moderate or severe MR. Both the aforementioned 
studies require further validation as the establishment of reliable recurrence predictors 
could be one of the most important elements guiding surgery decision. 
Myocardial viability has been studied for its impact on survival by Pu et al.(
77
) 
but has not been studied as a potential predictor of regurgitation recurrence. 
Mitral valve re-operations 
Interestingly enough, the higher rates of regurgitation recurrence associated with 
MVr do not correlate, in the majority of studies, with significantly higher reoperation 
rates. Through the use of regression analysis, Lorusso et al.
67
 concluded, however, that 
mitral valve repair was a strong predictor of reoperation (hazard ratio, 2.84; P<.001). 
The meta-analysis by Virk et al.
73
 also noted an increased trend towards reoperation 
among MVr patients, when earlier studies with low use of subvalvular apparatus 
preservation were excluded from the sensitivity analysis.  
Ecocardiographic dimensions 
Given their retrospective nature, the majority of published papers do not possess 
comprehensive reports on echocardiographic measurements (LVEF, LVESD, LVEDD) 
and even fewer report on post-operative evolution. However, the few that do report 
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improved left ventricular ejection fraction and reduced end-systolic and end-diastolic 
diameters after surgery. There was no significant difference between techniques in 
regards to post-operative geometric improvement.
47,78,79
 
Quality of life 
Perhaps insufficiently investigated as an outcome, there have been few noted 
differences in quality of life scores between patients undergoing different techniques. 
Goldstein et al. reported greater overall improvement on the Minnesota Living with 
Heart Failure questionnaire scores among patients undergoing MVR (mean change in 
heart-failure symptoms from baseline was 20.0 in the repair group versus 27.9 in the 
replacement group [P = 0.07]). There was also greater improvement from baseline 
scores among patients who did not have regurgitation recurrence (26.6 for patients 
without recurrence vs 16.2 those with recurrence). These differences only became 
apparent after the 12-month mark.
62
 However, in terms of NYHA class, there were no 
significant differences in improvement between the different techniques. 
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Potential Treatment Modalities 
Improved Mitral Valve Repair 
New approaches have been recently under analysis, in an attempt to counter the 
challenge posed by continuous leaflet tethering despite reductive annuloplasty and 
improve current outcomes for mitral valve repair. In contrast to MVR, where complete 
subvalvular apparatus preservation has shown to improve outcomes
54
, recent works 
have studied the use of partial chordal cutting (CC) during MVr, in patients with 
pronounced leaflet angling, as a way to decrease leaflet tethering without causing 
prolapse and improve coaptation (Figure 11). Messas et al. performed the first studies, 
both in vitro and in vivo, with sheep valves and positive outcomes, albeit in a reduced 
number of subjects.
80,81
 It was not until 2014 that Calafiore et al. reported on human 
subjects, concluding that in patients with a bending angle <145° in the anterior leaflet 
and coaptation depth ≤10 mm, CC was related to less MR recurrence and persistence, 
improved EF, and lower NYHA class when compared to subjects undergoing solely 
restrictive annuloplasty.
82
 However, the groups included only 26 propensity-matched 
patients each, with the technique requiring further validation.  
 
Figure 11 – Partial chordal cutting as an adjuvant to MVr. 
The association of an edge-to-edge (Alfieri) procedure to restrictive annuloplasty 
has had some positive results (Figure 12). Bhudia et al.(
83
) reported a low risk of it 
causing mitral stenosis but recommended the use of other techniques for IMR patients, 
due to worse outcomes comparetively to other-etiology MR’s. However, these less 
positive outcomes can be attributed to the already described worse baseline status of 
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IMR patients, and did not compare the use of edge-to-edge procedure with restrictive 
annuloplasty to those without Alfieri procedure. De Bonis et al.(
84
) performed such a 
comparison and noted a significant improvement in the durability of the repair. 
However, it is of note that the study also included idiopathic dilated cardiomyopathy 
patients (26 of 77 patients). 
          
Figure 12 – Edge-to-edge Alfieri procedure 
Percutaneous Coronary Intervention (PCI) 
Although the use of Percutaneous Coronary Intervention (PCI) (Figure 13) has 
been shown to improve IMR grade, by itself, in 1/3 of the patients studied by Yousefzai 
et al.(
85
), it falls short when compared to CABG. Kang et al.(
86
) performed such a 
comparison and concluded that although survival and cardiac mortality rates were not 
significantly different between IMR patients undergoing PCI or CABG, the event-free 
survival rates were significantly higher in the CABG group. For 45 propensity score-
matched pairs, the risk of cardiac events was also significantly lower in the CABG 
group than in the PCI group (hazard ratio, 0.499; 95% CI, 0.251 to 0.990; P=0.043). 
 
Figure 13 – Percutaneous Coronary Intervention (PCI) 
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Percutaneous Valve Procedures 
Percutaneous valve approaches are still at an early stage of development. The 
most well studied of these procedures is the MitraClip procedure, which is a catheter-
based device designed to approximate the mitral valve leaflets through an edge-to-edge 
method similar to the Alfieri procedure, while the heart is beating (Figure 14). In the 
phase II EVEREST trial, 279 patients were randomized in a 2:1 ratio to undergo 
percutaneous repair with MitraClip (n = 184) or conventional MVr or MVR (n = 95). 
Most patients (73%) had degenerative etiology MR. In the intention-to-treat analysis, 
the rates of death (6%) were similar for MitraClip and surgery at 1 year. The frequency 
of 2+ MR was significantly higher after MitraClip, but the proportion of patients with 
grade 3+ or 4+ MR was not significantly different between the 2 groups at 2 years of 
follow-up (20% percutaneous group vs. 22% surgical group). The rate of reoperation for 
MV dysfunction was 20% for percutaneous group as compared with 2.2% in the 
surgical group. The combined primary efficacy endpoint of freedom from death, from 
surgery for MV dysfunction, and from grade 3+ or 4+ MR was 55% in the 
percutaneous-repair group and 73% in the surgery group (p = 0.007). The EVEREST II 
trial showed superior safety in the percutaneous-repair group as compared with the 
surgery group in an intention-to-treat analysis mostly due to a higher rate of bleeding 
requiring transfusion in the surgery group. It is of note that only a minority of the 
patients included (27%) were of ischemic etiology.
87
 A recent meta-analysis of this and 
other studies by D’Ascenzo et al.(88) established similar positive outcomes for a 
median-follow-up of 6 months. The latest ESC guidelines for heart failure from 2016 
note that the technique may be useful in ‘inoperable’ IMR patients.44  
 
Figure 14 – MitraClip Percutaneous Mitral Valve Repair System 
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Figure 15 – CARILLON® Mitral Contour System 
The other system that has been studied specifically for patients with chronic 
IMR is the CARILLON® Mitral Contour System, which takes advantage of the 
proximity of the coronary sinus to the mitral annulus to deploy a proximal and a distal 
anchor, thereby reducing annular area and improving coaptation (Figure 15). The 
CARILLON Mitral Annuloplasty Device European Union Study(
89
) and the TITAN 
trials(
90
) have both noted reduction in regurgitant volume, LV dimensions and an 
increase in the 6-minute walking distance, compared to the control groups in the studies. 
However, each of the studies included under 40 patients, requiring further validation 
and perhaps comparison with surgical options (though the system is more suited to 
sicker patients who do not posess indication for surgery). 
The latest guidelines for valvular heart disease (2012) refer that the edge-to-edge 
angioplastic procedure may be useful for patients without excessive leaflet tethering, 
while pointing out its low procedural risk. They note that data on this procedure needs 
to be confirmed by larger series with longer follow-up and randomized clinical trials. 
The currently held position towards coronary sinus angioplasty is that information is 
scarce and that it requires further validation. Since 2012, there has not been enough new 
relevant work surrounding the Carrilon system, reason as to why further studies are still 
needed to make any kind of recommendations. 
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Conclusions  
There has been a shifting trend in recent years in regard to the discussion for the 
pathophysiology and treatment of Ischemic Mitral Regurgitation. As surgical techniques 
are perfected and becoming standardized across the different Cardiac Surgery centres, 
stronger evidence arises from randomized clinical trials and echocardiographic studies.  
The evidence available from randomized trials continues to suggest that the post-
operative mortality for IMR patients is superior to that of primary MR and that the 
addition of mitral valve surgery does not significantly improve survival, when 
compared to patients who only undergo bypass surgery. However, the single 
randomized trial that performed this comparison, by Michler et al., only studied patients 
with moderate IMR, and such results may not apply to severe IMR patients, for which it 
is still recommended. 
Previously widely held notions on the origin of Ischemic Mitral Regurgitation, 
such as the importance of papillary muscle necrosis, have been gradually debunked as 
more important mechanisms, such as LV dilatation and papillary muscle displacement, 
are pinpointed and further our accurate understanding of IMR. While older studies 
reported superior outcomes with mitral valve repair in patients with IMR, the use of 
propensity scoring and randomization have established mitral valve replacement as the 
more durable alternative. Notwithstanding, mitral valve repair still has its merits for 
being the approach with lower 30-day mortality. These new developments have, 
therefore, given us as much new valuable information as they have made it seemingly 
harder to declare either Mitral Valve Repair or Mitral Valve Replacement as the 
superior technique. The still small number of patients included in randomized clinical 
trials, as well as its under-3-years follow-up period, are limitations which needs to be 
amended through the performance of more randomized trials with follow-up periods 
beyond this mark. 
As the differences between outcomes in these techniques become smaller, it 
becomes essential to determine clinical and echocardiographic predictors of 
regurgitation recurrence (during MVr) that can help surgeons in deciding which 
technique to use (as LV wall dyskinesis and leaflet tethering have been pointed out to 
be). The presence of said predictors should encourage the surgeon in preferring the 
more durable alternative (albeit with higher operative mortality) of mitral valve 
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replacement. Further studies that include only IMR patients, work with rigorous pre- 
and post-operative measurements and access the patients’ baseline comorbidities are 
essential to establish reliable predictors. 
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